Cellectar Biosciences, Inc. · NASDAQ:CLRB
Cellectar Biosciences — Investor Presentation (October 2026)
41 slides from Cellectar Biosciences's investor presentation, October 2026
Slide 1: Corporate Presentation
Corporate Presentation NASDAQ: CLRB October 2026 Confidential. For Internal Use Only |. For fonts to display correctly, make sure Roboto is downloaded & installed Roboto
Slide 2: Forward-Looking Statements and Disclaimers
Forward-Looking Statements and Disclaimers This presentation contains forward-looking statements. Such statements are valid only as of today, and we disclaim any obligation to update this information. These statements are only estimates and predictions and are subject to known and unknown risks and
Slide 3: Overview
Overview Discovering and Developing the Next Generation of Phospholipid Drug Conjugates (PDC’s) • Initiated Phase 3 Confirmatory Trial of iopofosine I 131 in Waldenstrom’s macroglobulinemia (WM) – Achieved statistically significant response rate (primary endpoint) in Phase 2b CLOVER WaM pivotal tria
Slide 4: Formula for Value Creation
Formula for Value Creation Strategic Growth and Expansion • Optimize global WM regulatory approval pathway for iopofosine I 131 – Phase 3 confirmatory trial supports global approval; potential US accelerated approval 2H27 – EMA Conditional Marketing Authorization submission based upon U.S. potential
Slide 5: Pipeline
Pipeline Compound Disease State Preclinical Phase 1 Phase 2 Phase 3 Waldenström IRIS WaM* Phase 3 Confirmatory Trial Ongoing macroglobulinemia Iopofosine I 131 Iodine-131 β-emitting radioconjugate b-cell Malignancies DLBCL, MM & NHL Pediatric High-grade Glioma Phase 1b CLR 121125 Iodine-125 Solid Tu
Slide 6: Phospholipid Drug Conjugate (PDC) Platform Mechanism of Action
Phospholipid Drug Conjugate (PDC) Platform Mechanism of Action (MOA)
Slide 7: PDC Platform MOA: Lipid Rafts
PDC Platform MOA: Lipid Rafts The Role of Lipid Rafts as a Universal Target in Cancer Lipid rafts and play an essential role in cancer Lipid Rafts Play an Influential Role in Cancer Enhanced oncogenic signaling • Concentrate and stabilize growth factor receptors Survival and resistance to apoptosis
Slide 8: PDC Platform MOA: Universal, Intracellular Targeting with Diverse Payloads
PDC Platform MOA: Universal, Intracellular Targeting with Diverse Payloads Enhanced Targeting, Limited Resistance, No Need for Bystander Effect, Improved Toxicity INTERCELLULAR DELIVERY AND RELEASE OF PAYLOAD SPECIFIC TARGETING OF LIPID RAFT ON CANCER PDC CONTAINING DESIRED PAYLOAD WITH BY TRANSMEMB
Slide 9: PDC Platform MOA: Lipid Rafts Mediate Entry into Tumor Cells
PDC Platform MOA: Lipid Rafts Mediate Entry into Tumor Cells Overabundance of Lipid Rafts on Tumor Cells Lipid Rafts Fluorescent-labeled with Cholera Toxin Subunit Methyl-β-cyclodextrin (MBCD) Selectively Disrupts Lipid Rafts A549 NSCLC A549 labeling vs Fibroblast Prostate Pancreatic Co-cultured No
Slide 10: Clinically Validated Platform and Payload Flexibility
PDC Platform MOA: Lipid Rafts Mediate Entry into Tumor Cells Clinically Validated Platform and Payload Flexibility Iopofosine I 131 Iopofosine I 124 100 Best Response by r/r WM Patient (n=55) 75 50 IgMReduction (%) 25 0 * (25) * * * * (50) * * * ** (75) * * ** (100) * PD SD MR PR CR/ VGPR 80 Best Re
Slide 11: Phospholipid Radioconjugate (PRC) program: Iopofosine I 131 Waldenstrom Macroglobulinemia
Phospholipid Radioconjugate (PRC) program Beta Emitter Iopofosine I 131 Waldenstrom Macroglobulinemia
Slide 12: Phase 2b Global CLOVER-WaM Pivotal Trial
PRC Iopofosine I 131: Phase 2b Global CLOVER-WaM Pivotal Trial Schema Enrollment Criteria Treatment and Primary Evaluation Period Long Term Follow-up (3 years) Endpoints: Key Secondaries: WM Patients who Major Response Rate DoR, TFR, ORR received 2 Prior lines of therapy, including failed or subopti
Slide 13: CLOVER-WaM Pivotal Trial: Patient Demographics
PRC Iopofosine I 131: Phase 2b Global CLOVER-WaM Pivotal Trial Demographics - Patient Characteristics Data Cut-off September 30, 2024 Patient Characteristics Patient Characteristics Safety population, n 65 Median Prior Lines of Therapy, n (range) 4 (2-15) Median age, years (range) 70 (50-88) Prior T
Slide 14: Efficacy Data - Best Serum IgM Response by Patient
PRC Iopofosine I 131: Phase 2 b CLOVER-WaM Pivotal Trial Efficacy Data - Best Serum IgM Response by Patient Evaluable Efficacy Population (n=55) Evaluable Efficacy Population (n=55) ORR = 80% MRR = 58.2% DCR = 98.2% ORR = 83.6% MRR = 61.8% DCR = 98.2% 100% 100% VGPR/CR Rate = 9.1% VGPR/CR Rate = 14.
Slide 15: Duration of Response & Progression Free Survival Analysis
PRC Iopofosine I 131: Phase 2b CLOVER-WaM Pivotal Trial Efficacy Data - Duration of Response & Progression Free Survival Analysis (mITT)– Data cutoff Dec 2025 Median DoR = 533 Days / 17.8 months - + = censored Median PFS = 406 Days / 13.5 months - + = censored With only Four ~20-minute Infusions, Io
Slide 16: Sub-analysis of BTKi Refractory vs BTKi Exposed
PRC Iopofosine I 131: CLOVER-WaM Efficacy Data Sub-analysis of BTKi Refractory vs BTKi Exposed: DoR and PFS in Patients (mITT) – Data cut-off Dec 2025 BTKi Exposed Median DoR = 546 days / 18.2 months: BTK Refractory Median DoR = 546 Days / 18.2 months - BTKi Exposed Median PFS = 476 days / 15.9 mont
Slide 17: Comparison to Only Published Data Set
PRC Iopofosine I 131: CLOVER-WaM Efficacy Data Sub-analysis of BTKi Refractory vs BTKi Exposed: Comparison to only published data set Comparison of Patient Populations Frustaci Study CLOVER WaM Trial • Median Age 75.5 • Median Age 70 • Refractory to BTKi – 69.2%: Intolerant to BTKi – 30.2% • Refract
Slide 18: Safety Data - Observed Cytopenias
PRC Iopofosine I 131: Phase 2b CLOVER-WaM Pivotal Trial Safety data - Observed Cytopenias Consistent with Treatment of Hematologic Malignancies Any grade Grade ≥3 Most common TEAE* (>10% patients), n (%) Most common TEAE* (>10% patients), n (%) n=65 n=65 Hematologic Toxicities Thrombocytopenia 53 (8
Slide 19: Adverse Event Comparison to BTKi's
PRC Iopofosine I 131: Adverse Event Comparison to BTKi’s Safety data – Treatment Emergent Adverse Events of Iopofosine as Compared to the Only Approved WM Therapies Adverse Event Occuring in Zanubrutinib (n=101) Ibrutinib (n=98) Iopofosine I 131 (n=227) >10% All Grades All Grades (%) Grade >3 (%) Al
Slide 20: Phase 3 IRIS WaM Confirmatory Trial for Full Approval
PRC Iopofosine I 131: Phase 3 IRIS WaM Confirmatory Trial for Full Approval Waldenstrom’s macroglobulinemia Second Line or Iopofosine I 131 Primary Endpoint: PFS Later, Immediately (full approval) Post-BTKi Comparator: Secondary Endpoints: Randomized 1:1 rituximab cyclophosphamide MRR, safety dexame
Slide 21: U.S. & E.U. WM Market Opportunity
PRC Iopofosine I 131: U.S. & E.U. WM Market Opportunity Addressable Patients in a Concentrated Market with High Unmet Need US Prevalent Patient Population Based Upon Claims = 26,000 5 EU Prevalent Patient Population = ~36,0008 ~11,500 ~4,700 ~1,000 ~12,600 ~5,000 Concentrated 2nd line 3rd line or gr
Slide 22: Phase 1b/2a Dosimetry Trial
PRC Iopofosine I 131: Phase 1b/2a Dosimetry Trial Patient Selection: All Comers Waldenstrom’s macroglobulinemia Trial Schematic Trial Overview 2 cycles (4 doses – 15mCi/m2 per dose): 20 - 30 patients • Imaging and therapy study Treatment and Evaluation Period (1 year) • Population: Front line or lat
Slide 23: Iopofosine I 131 Additional Indications
Phospholipid Radioconjugate (PRC) program Beta Emitter Iopofosine I 131 Additional Indications
Slide 24: r/r Multiple Myeloma Best Response
PRC Iopofosine I 131: r/r Multiple Myeloma Best Response Waterfall Plot of All Multiple Myeloma Patients Multiple myeloma cell lines Best Response by Patient (n=64) 80 Patients receiving at least 60mCi <60 mCi TAD 60 32% ORR >60 mCi TAD CLR 1501 96% DCR Quad-class refractory 40 3.3 months mPFS in po
Slide 25: Broad Clinical Activity Beyond WM
PRC Iopofosine I 131: Broad Clinical Activity Beyond WM Refractory Primary CNS Lymphoma Relapsed Pediatric High-Grade Glioma Complete Response Extended PFS (~12 months) Recurrent Head & Neck Cancer Refractory Diffuse Large B-cell Lymphoma 30% ORR with 10% CRR – CR PFS 6.8 years 73% ORR with 64% CRR
Slide 26: PRC Program: Auger Emitter CLR 125 (TNBC)
Phospholipid Radioconjugate (PRC) Program Auger Emitter – CLR 125 (TNBC)
Slide 27: CLR 125: Auger Emitter
PRC CLR 12125 (CLR 125): Auger Emitter ( I) 125 Microenvironment, Tumor Biology & Isotope Properties Drive Safety and Efficacy Primary Mechanism of Penetrating Power Relative Biologic Composition Cell Death (Emission Distance) Effect 2 protons Double strand 50 – 100um Alpha Particles ~5 2 neutrons D
Slide 28: Enhanced Tumor Absorbed Dose Results in Increased Cell Killing
PRC CLR 121125 (CLR 125): Auger Emitter ( I) 125 Enhanced Tumor Absorbed Dose Results in Increased Cell Killing CLR 124 CLR 125 CLR 131 110% 100% Brain Brain Breasts Breasts 100% 90% Stomach Stomach Heart 90% Heart 80% Kidneys Kidneys Liver 80% Liver 70% Lungs Lungs Red Marrow 70% Red Marrow 60% Spl
Slide 29: Offers Benefits Vs Other Auger Emitters
PRC CLR 121125 (CLR 125): Auger Emitter ( I) 125 Offers Benefits Vs Other Auger Emitters Why I-125? • One of the highest Auger electron emitters • 57-day half-life enhanced outcomes • No Beta or Gamma emissions observed Existing data set supports Phase 1b/2 clinical Trial AE = Auger electron X = X
Slide 30: TNBC - Statistically Significant Activity, Well Tolerated In Vivo
PRC CLR 121125 (CLR 125): Auger Emitter ( I) 125 TNBC - Observed Statistically Significant Activity and Well Tolerated In Vivo CLR 125 structurally identical to iopofosine I 131; potentially reduced B development risk A CLR 125 tested in MDA-MB-231 triple negative breast cancer • Observed significan
Slide 31: Phase 1b Dose Finding Trial in Relapsed TNBC
PRC CLR 121125 (CLR 125): Auger Emitter ( I) 125 Phase 1b Dose Finding Trial in Relapsed Triple Negative Breast Cancer 3 months 6 months 12 months Trial Schematic Phase 1 Trial Overview Key Inclusion/Exclusion Criteria 2 doses per cycle: 15 patients per arm • Imaging and therapy study • Confirmed TN
Slide 32: PRC Program: Alpha Emitters CLR 225 (Pancreatic)
Phospholipid Radioconjugate (PRC) Program Alpha Emitters – CLR 225 (Pancreatic)
Slide 33: CLR 225: Tumor Volume Reduction and Survival Benefit in Pancreatic Cancer
PRC CLR 121225 (CLR 225): Alpha Emitter ( Ac) 225 Tumor Volume Reduction and Survival Benefit in Pancreatic Cancer MIA PaCa-2 Time to Progression BxPC-3 Time to Progression 100 100 Control 90 90 100 nCi 80 Control Progression Free (%) 80 500 nCi Progression Free (%) 70 250 nCi 70 250 nCi 60 60 500 n
Slide 34: Biodistribution in Pancreatic Model
PRC CLR 121225 (CLR 225): Alpha Emitter ( Ac) 225 Biodistribution in Pancreatic Model 40 4 hours 24 hours 72 hours 30 144 hours %ID/g 20 10 0 Brain Bone Muscle Small Large Stomach Pancreas Liver Spleen Kidney Heart Blood Tumor Intestines Intestines High and Prolonged Tumor Uptake with Low Normal Tis
Slide 35: CLR 225: Prostate Cancer Tumor Volume Reduction
PRC CLR 121225 (CLR 225): Alpha Emitter ( Ac) 225 Tumor Volume Reduction and Survival Benefit in Prostate Cancer • MyC-CaP and TRAMP-C1 prostate MyC-CaP TRAMP-C1 cancer xenograph models dosed after tumors reached 200mm3 • Doses of 200nCi or 500nCi • Dosimetry data showed increased uptake in TRAMP-C1
Slide 36: Phase 1 Clinical Trial in Pancreatic Cancer Prepared
PRC CLR 121225 (CLR 225): Alpha Emitter ( Ac) 225 Phase 1 Clinical Trial in Pancreatic Cancer Prepared – Initiation TBD Excellent labeling efficiency with 225Ac Phase 1 trial design Imaging and therapy trial Simplified reaction process Dose escalation utilizing an accelerated titration design (allow
Slide 37: Financials: Capitalization
Financials Capitalization BIOSCIENCES
Slide 38: Financial Summary
Financial Summary Cash Position as of June 30, 2026 (millions) $34.0M Capitalization as of August 13, 2026 Common Stock Outstanding 9,452,108 Pre-Funded Warrants 8,010,790 May 2026 Series A Common Warrant ($2.65 strike) 13,206,026 May 2026 Series B Common Warrant ($2.65 strike) 13,206,026 May 2026 S
Slide 39: Formula for Value Creation
Formula for Value Creation Strategic Growth and Expansion • Optimize global WM regulatory approval pathway for iopofosine I 131 – Phase 3 confirmatory trial supports global approval; potential US accelerated approval 2H27 – EMA Conditional Marketing Authorization submission based upon U.S. potential
Slide 40: Thank You
Thank You
Slide 41: Executive Management Team
Executive Management Team Greater than 95 years combined leadership experience James Caruso Jarrod Longcor Chad Kolean President, CEO and Director Chief Operating Officer Chief Financial Officer Confidential. For Internal Use Only |. For fonts to display correctly, make sure Roboto is downloaded & i
Cellectar Biosciences — Investor Presentation (October 2026) on 6ix